You searched for oncology - Page 100 of 100

News and Trends 22 Nov 2014

After AstraZeneca Turned Down Pfizer’s Bid, Merck Took the Opportunity

Pharmaceutical giants Merck and Pfizer have agreed a deal to develop and market immunotherapy agents to fight cancer. Now, the last Pfizer’s proposal to AstraZeneca is pending. Merck will get an upfront payment of €682 million from the U.S. drugmaker for sharing rights to develop its experimental immunotherapy drug with Pfizer. It is also eligible […]

November 22, 2014 - 2 minutesmins - By Julie Lellouche

News and Trends 14 Nov 2014

Onxeo confirms receipt of the $25M milestone payment from its US partner Spectrum

Onxeo, an innovative company specializing in the development of orphan oncology drugs, founded after the merger of BioAlliance Pharma and Topotarget, announces that it has received from his US partner Spectrum Pharmaceuticals the milestone payment of $25 million related to the approval of Beleodaq by the FDA. Early July 2014, Beleodaq was granted by the […]

November 14, 2014 - 3 minutesmins - By Joachim Eeckhout

News and Trends 6 Nov 2014

The First Patient Receives an Implant Pump System to manage Pleural Effusions

For the first time, a pleurapump system designed to manage chronic pleural effusions was implanted in a patient in Marseille (France). This is an innovative device from Sequana Medical AG, a private Swiss medical device company. Chronic pleural effusions is recurrence of excess fluid which collects around the lungs. The most common causes of it are congestive heart […]

November 6, 2014 - 2 minutesmins - By Julie Lellouche

CSL pays 275m to acquire Novartis flu vaccines manufacturing sites strict xxl

News and Trends 31 Oct 2014

Novartis steps down completely from Vaccines’ Business

Novartis divests its influenza vaccines business to CSL Limited, an Australian company, for an agreed price of 219 million euros, completing the last deal with GSK a few months ago. This is a strategic move of Novartis; they plan to focus on the pharmaceutical business, ophthalmology (Alcon) and generics (Sandoz). Last year, influenza vaccine business reached a turnover of 1 […]

October 31, 2014 - 2 minutesmins - By Julie Lellouche

News and Trends 16 Oct 2014

A Smart Collaboration to Diagnostic and Fight Cancer

New Oncology announced that it has entered into a collaboration agreement with Gustave Roussy Cancer Campus, Paris. Under this agreement, New Oncology (Cologne-based German Biotech company) will perform comprehensive parallel multigene testing to identify therapeutically relevant alterations in cancer-related genes. New Oncology will apply its proprietary diagnostic platform ‘NEO’, which allows rapid sample processing compatible with both […]

October 16, 2014 - 3 minutesmins - By Julie Lellouche

News and Trends 15 Oct 2014

New Peptide Technology Against Cancer bags 25 Million Euros

Bicycle Therapeutics, a next generation biotherapeutics UK-based company developing first-in-class bicyclic peptides, announced that it had secured an equity financing of €25 million for the clinical development of therapeutic bicycle drug candidates in oncology. Bicycle has used its proprietary bicyclic peptide technology that enables to discover a new class of drug candidates, which have similar selectivity […]

October 15, 2014 - 3 minutesmins - By Julie Lellouche

News and Trends 15 Oct 2014

Recently Launched Company Rigontec already Raised 9,45M Euros against Cancer

Rigontec GmbH, a German privately held biopharmaceutical company developing RNA-based immunotherapeutics for the treatment of cancer and viral diseases, announced the first closing of its Series A financing round, raising €9.45 million. Rigontec was launched in January 2014 as a spin-out of the Institute for Clinical Chemistry and Clinical Pharmacology at the University of Bonn, Germany. The Company’s […]

October 15, 2014 - 2 minutesmins - By Julie Lellouche

csm ganymed start bilder04 new 7ec1db04d4

News and Trends 2 Oct 2014

BioNTech and Ganymed Pharmaceuticals Open One of the Largest Research Facilities in Germany

BioNTech AG and Ganymed Pharmaceuticals AG, two leading German biotechnology companies, announced today the joint- opening of a new headquarters and research facility of approximatively 10,000 square-meters. The new facility brings together 300 employees and is located close to academic institutions (Johannes-Gutenberg University), hospitals (University Medical Center) and cancer research institutions such as the leading translational oncology […]

October 2, 2014 - 2 minutesmins - By Julie Lellouche

News and Trends 30 Sep 2014

New Collaboration for New Cancer Therapies

Medimmune, the global biologics research and development arm of Anglo-Swedish drug major AstraZeneca, has entered into a collaboration to establish a joint lab in Cambridge, UK, with Cancer Research Technology, the commercial arm of Cancer Research UK. The new laboratory will be the first partnership of its kind of both organizations, and will focus on […]

September 30, 2014 - 2 minutesmins - By Julie Lellouche

News and Trends 25 Sep 2014

A New Financial Hope for Start-ups Focused on Cancer

Aglaia is a new venture capital fund that will invest in about ten to fifteen biotechnology start-ups developing groundbreaking technologies to prevent and cure cancer. The Dutch venture has announced the launch of Aglaia Oncology Fund II. Investors contribute with $65M (EUR 51M) for the fund, to reach $80M (EUR 63M) to $100M (EUR 80M). Like […]

September 25, 2014 - 2 minutesmins - By Julie Lellouche

News and Trends 3 Sep 2014

Affimed secures almost $30M in Financing to continue its clinical development

Affimed Therapeutics today announced that it has closed a $15.7 million (€11.7 million) Series E equity funding led by Affimed’s current investors Aeris Capital, BioMedInvest, LSP Life Sciences Partners, Novo Nordisk A/S and Orbimed. In addition, the Company has signed a $14 million (€10.5 million) loan agreement with Perceptive Advisors, leading to a total of […]

September 3, 2014 - 2 minutesmins - By Joachim Eeckhout

News and Trends 19 Aug 2014

Ablynx gain €2.1m to develop a novel Nanobodies for Ocular applications

Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases, including inflammation, haematology, oncology and pulmonary disease. Ablynx today announced that it has been awarded a €2.1 million grant by the Flemish Agency for […]

August 19, 2014 - 2 minutesmins - By Joachim Eeckhout

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us